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Abstract
Background: Platelets are small anucleated blood particles that play a key role in the control of bleeding. Platelets
need to be activated to perform their functions and participate in hemostasis. The process of activation is
accompanied by vast protein reorganization and posttranslational modifications. The goal of this study was to
identify changes in proteins in platelets activated by different agonists. Platelets were activated by three different
agonists - arachidonic acid, collagen, and thrombin. 2D SDS-PAGE (pI 4-7) was used to separate platelet proteins.
Proteomes of activated and resting platelets were compared with each other by Progenesis SameSpots statistical
software; and proteins were identified by nanoLC-MS/MS.
Results: 190 spots were found to be significantly different. Of these, 180 spots were successfully identified and
correspond to 144 different proteins. Five proteins were found that had not previously been identified in platelets:
protein CDV3 homolog, protein ETHE1, protein LZIC, FGFR1 oncogene partner 2, and guanine nucleotide-binding
protein subunit beta-5. Using spot expression profile analysis, we found two proteins (WD repeat-containing
protein 1 and mitochondrial glycerol-3-phosphate dehydrogenase) that may be part of thrombin specific activation
or signal transduction pathway(s).
Conclusions: Our results, characterizing the differences within proteins in both activated (by various agonists) and
resting platelets, can thus contribute to the basic knowledge of platelets and to the understanding of the function
and development of new antiplatelet drugs.
Background
Platelets are small anucleated blood particles derived
from megakaryocytes in the bone marrow. They play a
key role in the control of bleeding (hemostasis) by the
formation of a vascular plug and the release of stimula-
tory molecules participating in hemostasis. Platelets cir-
culating in the blood are normally maintained in a
resting state; but upon a disruption of the integrity of
the vascular endothelium or an alternation in the shear
stress of the blood flow, platelets become activated. Pla-
telets adhere to the damaged endothelium, coadhere
(aggregate), and release both low molecular weight com-
pounds and proteins [1]. This process of activation is
accompanied by vast protein reorganization and post-
translational modifications. These platelet proteome
changes are not yet fully understood and can lead either
to thrombotic or bleeding disorders [1,2]. Therefore,
understanding the mechanisms of platelet activation is
crucial for the treatment of platelet-involved diseases.
Although the number of identified platelet proteins
increases every year, there is still a lack of the supple-
mental data necessary to clearly establish the role of
these proteins in platelet metabolism. Differential pro-
teomics, together with the identification of protein mod-
ification by immunoblot or mass spectrometry (MS), are
usually used to provide this type of data. In recent years
proteomics have become the most popular and broadly
used method for studying platelet biology; with several
studies exploring both resting and activated platelet pro-
teomes, platelet subproteomes (platelet granules, mem-
brane systems, phosphoproteome, etc.), or studying
proteome changes by comparing activated and resting
platelets [3-14].
The proteomics methodology enables the exploration
of hundreds or even thousands of proteins in a sample
using a combination of orthogonal electrophoretic
methods, high performance liquid chromatography* Correspondence: pavel.majek@uhkt.cz
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(HPLC), and MS analyses. Moreover, proteome changes
such as posttranslational modifications can be effectively
observed only by using proteomic methods. 2D gel elec-
trophoresis has become one of the most widespread
proteomic techniques used in proteome analysis (in
spite of some disadvantages, such as in the exploration
of low-abundance, basic, or low molecular weight pro-
teins). Together with differential image analysis software
processing and MS protein identification, these methods
are the corner stone of recent proteomic research. Since
blood platelets are anucleated particles, the very low
levels of retained megakaryocyte-derived mRNA and
mitochondrial transcripts hampers genome and tran-
scriptome analyses [15].
The goal of this proteomics study was to identify
changes within proteins, in platelets activated by differ-
ent agonists. Three potent platelet agonists were chosen
for platelet activation: arachidonic acid (AA), collagen,
and thrombin. All proteomes of either resting or




Thrombin, prostaglandin E1, SDS, acrylamide, bis-acry-
lamide, carrier ampholytes, urea, thiourea, CHAPS,
iodoacetamide, TEMED, acetonitrile, methanol (HPLC
grade) and all antibodies were purchased from Sigma-
Aldrich, Prague (Czech Republic). Immobilized pH gra-
dient (IPG) strips (pH 4-7) and the electrophoresis
instruments were acquired from Invitrogen (Carlsbad,
CA, USA). Collagen and AA were purchased from Bio/
Data (Horsham, PA, USA). Formic acid, DTT, ammo-
nium persulfate, ammonium bicarbonate, and ammo-
nium sulfate were obtained from Fluka Chemie (Buchs,
Switzerland). Serva Blue G and Serva Unstained SDS
PAGE Protein Marker 6.5 - 200 kDa were acquired
from SERVA (Heidelberg, Germany). Sequencing grade,
modified trypsin was obtained from Promega (Madison,
WI, USA). All other chemicals were purchased from
PLIVA-Lachema (Brno, Czech Republic) and were of
analytical grade.
Platelet isolation and activation
Human whole blood was obtained from healthy volun-
teers who had not been on medication for the previous
14 days. All tested individuals agreed to this study at the
time of blood collection. All samples were obtained in
accordance with the Ethical Committee regulations of
the Institute of Hematology and Blood Transfusion.
Washed blood platelets were isolated by the differen-
tial centrifugation of blood collected into a ACD (65
mM citric acid, 85 mM citrate, 111 mM glucose) solu-
tion 8.1:1.9 (v/v). Platelet rich plasma (PRP) was
obtained by the centrifugation of blood at 250 × g at 37°
C for 15 min. PRP with the addition of prostaglandin E1
(1 μM, final concentration) was incubated in a water
bath (37°C for 10 min) and centrifuged at 1000 × g at
37°C for 10 min. The platelet pellet was resuspended in
a Ca2+ free Tyrode’s buffer (140 mM NaCl, 3 mM KCl,
12 mM NaHCO3, 0.4 mM NaH2PO4, 2 mM MgCl2, 5.6
mM glucose; pH 6.2) in the presence of 1 μM prosta-
glandin E1 and centrifuged at 600 × g at 37°C for 10
min. The platelet pellet was then resuspended in a Tyr-
ode’s buffer (140 mM NaCl, 3 mM KCl, 12 mM
NaHCO3, 0.4 mM NaH2PO4, 1 mM MgCl2, 2 mM
CaCl2, 5.6 mM glucose; pH 7.4) to a final concentration
of 5 × 108/mL (standard platelet suspension), and incu-
bated at 37°C for 30 min. The platelet count in PRP was
estimated by a Onyx Coulter Counter blood counter
(Beckman Coulter, Brea, CA, USA).
Standard platelet suspension (SPS) was divided into
four aliquots. Activation of platelets was performed in
polypropylene tubes at 37°C while stirring. The
described amounts of added agonists were optimized
and checked turbidimetrically [16] using a four-channel
PAP4 aggregometer (Bio/Data). Tests were performed at
37°C in cuvettes stirred at 1000 rpm. Finally, the opti-
mized amounts of agonists were 10 μL of AA (5 mg/
mL) to 500 μL of SPS; 10 μL of collagen (1.9 mg/mL) to
500 μL of SPS; and 10 μL of thrombin (final activity of
thrombin 2 NIH U/mL) to 200 μL of SPS. Platelets were
stimulated for 10 min (each agonist). The whole platelet
suspension aggregated with either agonist was added to
four times of the sample volume of cold acetone (-20°
C), incubated at -20°C for at least 2 hr, and centrifuged
at 15,000 × g at 4°C for 10 min. If not used immediately,
the pellets were rapidly frozen and stored at -70°C.
Two-dimensional gel electrophoresis
Pellets were resuspended in a sample buffer (7 M urea,
2 M thiourea, 4% w/v CHAPS, 65 mM DTT, 1.5% v/v
ampholytes, and a trace of bromophenol blue) - 320 μL
of sample buffer per pellet, from 1 mL of standard pla-
telet suspension. Samples were then centrifuged at
37,500 × g at 20°C for 1 hr. IPG strips (pI 4-7, 7.7 cm)
were rehydrated in 155 μL of the sample for 16 hr at
room temperature. The conditions for IEF were: 100 V
for 40 min, 200 V for 20 min, 450 V for 15 min, 750 V
for 15 min, reaching 2000 V in 10 min, and 4000 Vh
(max 0.125 mA and 0.125 W per strip). If not used
immediately, strips were rapidly frozen and stored at
-70°C. Following IEF, strips were equilibrated for 20 min
in a DTT buffer (6 M urea, 50 mM Tris pH 6.8, 2% w/v
SDS, 1% w/v DTT, 30% v/v glycerol, and a trace of bro-
mophenol blue), followed by equilibration in an iodoace-
tamide buffer (6 M urea, 50 mM Tris pH 6.8, 2% w/v
SDS, 2.5% w/v iodoacetamide, 30% v/v glycerol, and a
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trace of bromophenol blue) for another 20 min. Proteins
were separated in two dimensions by SDS-PAGE, as
described previously [17] (8 × 10 cm, 5-15% gradient
gel, 3.75% stacking gel, 5°C, 30 mA/gel) using a P8SD
vertical electrophoresis separation system (Owl; Thermo
Scientific, Rochester, NY, USA). Following electrophor-
esis, the gels were stained with colloidal Coomassie blue
stain (17% w/v ammonium sulfate, 1.8% H3PO4, 35% v/v
methanol, and 0.12% Serva Blue G) for at least 24 hr
and destained with 1% acetic acid.
Image analysis
Scanned images (16-bit grayscale) were processed and
statistically evaluated with Progenesis SameSpots soft-
ware (Nonlinear Dynamics, Newcastle upon Tyne, UK).
Both manual and automatic alignment was used to align
the images. All four groups were compared with each
other and fold values as well as p-values of all spots
were computed by the above mentioned software using
one way ANOVA analysis. All spots were prefiltered
and manually checked before applying the statistical cri-
teria (Anova p < 0.05 and fold ≥1.2). Normalized spot
volumes, instead of spot intensity, were used in statisti-
cal processing. Protein identification involved only spots
that fulfilled the statistical criteria. Expression profiles
(dependence of logarithm of normalized volume on the
sample grouping) of all spots, as well as the dendrogram
of spot expression profiles, were created automatically
by the Progenesis SameSpots software. Because a simple
spot could contain more than one protein, the term
spot expression profile was used instead of the protein
expression profile. The dendrogram is a visual represen-
tation of the spot correlation data (with correlation ana-
lysis performed on the log normalized spot expression
levels). Spots are clustered according their closest corre-
lation. Spots with a high correlation value (close to 1)
show similar expression profiles. Experimental pI and
Mw values were estimated using the protein Mw mar-
ker, together with values of known and identified
proteins.
In-gel digest
Selected spots were excised from the gel and destained
in a 1:1 ratio of 100 mM NH4HCO3 and acetonitrile.
Destained gel pieces were dried with acetonitrile, rehy-
drated with 100 mM NH4HCO3, and dried with acetoni-
trile once again. Finally, vacuum dried gel pieces were
rehydrated in a trypsin solution (12.5 ng/μL of trypsin
in 25 mM NH4HCO3); and trypsin digestion was per-
formed at 37°C for 16 hr. Then, a 50% acetonitrile/0.1%
formic acid solution was added to gel pieces; and pep-
tides were extracted by agitation for 15 min. The super-
natant was recovered; and the previous extraction step
was repeated. The resulting supernatants were then
pooled, dried out, and dissolved in 2% acetonitrile/0.1%
formic acid.
Mass spectrometry analysis
An HCT ultra ion-trap mass spectrometer (Bruker Dal-
tonics, Bremen, Germany) with nanoelectrospray ioniza-
tion, coupled to a UltiMate 3000 nanoLC system
(Dionex, Sunnyvale, CA, USA) was used to perform MS
analysis. Tryptic peptides were desalted on a 300 μm
ID/5 mm length C18 PepMap 100 precolumn (Dionex)
and separated on a 75 μm ID/15 cm length C18 Pep-
Map 100 analytical column (Dionex). A gradient of acet-
onitrile was used to elute peptides (0% to 20% B for 2
min, 20% to 50% B for 15 min; mobile phase A: 2%
ACN/0.1% formic acid, mobile phase B: 80% ACN/0.1%
formic acid) at a flow rate of 300 nL/min. The nanoLC
system was connected to the MS using a PicoTip needle
(New Objective, Woburn, MA, USA) with an applied
voltage of 1500 V. The flow of the dry gas was 10 l/min
with a dry temperature of 160°C. We used the Standard -
Enhanced positive scan mode for CID data acquisition.
The scan ranges were 300 - 1500 m/z and 100 - 2500 m/
z for MS and MS(2) respectively. Three precursor ions
were selected during one autoMS(2) cycle; and active
exclusion (0.35 min, singly charged ions) was used. We
used esquireControl v6.2 software for data acquisition,
DataAnalysis v4.0 for data processing, and BioTools v3.2
(all Bruker Daltonics), together with MASCOT v2.2
(Matrix Science, London, UK) for database searching
(SWISS-PROT 57.0, 20403 sequences assigned to Homo
sapiens; and NCBInr 20090402, 222100 sequences
assigned to Homo sapiens). The following database
search parameters were utilized: taxonomy, restricted to
Homo sapiens; carbamidomethyl (C), selected as a fixed
modification and oxidation (M) as a variable modifica-
tion; the number of missed cleavages, up to 1; monoiso-
topic mass; and finally, mass tolerance of 0.1% for MS
and 0.5 Da for MS/MS. At least two unique peptides
were necessary to identify a protein.
Results
Platelet aggregation tests were performed on each sam-
ple to ensure full platelet activation (Figure 1). The
amounts of added agonists (as described in Methods)
were constant and sufficient to completely activate pla-
telets in all samples with all agonists.
A total of 40 gels were prepared throughout the experi-
ment. Scanned gel images were divided into four indivi-
dual groups according to platelet activation (resting
platelets, AA, collagen, and thrombin activated platelets,
respectively). One gel with the sample of collagen-
activated platelets was excluded from image analysis due
to a pattern distortion. Finally, each group analyzed by
the image analysis contained ten gel images, except for
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the collagen activated platelets, with nine gel images. All
four groups were mutually compared using one way
ANOVA analysis. Both manual and automatic image
alignment were used. Specific pre-filtering and statistical
criteria were applied to all spots that were automatically
detected by the Progenesis SameSpots software (in total
more than 2200 spots detected by the software). Applying
pre-filtering (edge and area exclusion, minimal spot area,
or normalized volume) altogether more than 1000 spots
remained in the analysis. Using statistical criteria in the
next step (Anova p < 0.05, minimum fold change 1.2), we
detected 190 spots that significantly differed in the nor-
malized volumes. Positions of these spots are presented
in an illustrative 2D gel image of resting platelets (Figure
2). The same gel image without spots is presented for a
better clarity in Figure 3.
Proteins in 180 of the 190 (95%) spots that differed
were successfully identified by nanoLC-MS/MS. At least
two unique peptides (fulfilling a minimal Mascot score)
were necessary to successfully identify a protein. Actu-
ally, three or more unique peptides were found in 91%
of proteins. The identified spots correspond to 144 dif-
ferent open reading frames. The list of spots including
the fold, Anova p-value, logarithm of normalized volume
with its standard deviation, both experimental and cal-
culated values of pI and MW, protein identification with
protein accession number, and sequence coverage is
summarized in Table 1 (See additional file 1: Table s1).
The fold value shows the fold difference between the
groups with the lowest and highest normalized volumes.
Figure 4 shows an example of six spots presented in
Table 1 (See additional file 1: Table s1) with their spot
expression profiles and representations of spots in
selected areas of illustrative gels from each group.
Whenever the calculated molecular weights of identified
proteins using 2D gel analysis were extremely different
from the molecular weights based on the LC-MS/MS
results with subsequent protein’s database search, we
distinguished the protein fragments from the full length
protein. Fragments of three different proteins were suc-
cessfully identified (filamin A/FLNA protein, thrombos-
pondin-1/thrombospondin-1 N-terminal domain, and
AP-1 complex subunit beta-1/unnamed protein product)
by searching NCBInr. They are each represented in the
list of spots (See additional file 1: Table s1) in brackets
below the original protein identification based on
Figure 1 Aggregation tests. An example of activation of platelets by the three agonists (arachidonic acid - blue trace, collagen - red trace, and
thrombin - green trace). Aggregation tests were performed on each sample of the analysis.
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database search. In twelve spots (32, 37, 48, 76, 80, 112,
126, 130, 145, 146, 177, 178) the matching of peptides
resulted in an ambiguous identification of proteins
(nevertheless all thus identified proteins are represented
in the Table 1 and separated by semicolons).
Based on the known properties the identified proteins
were categorized into several groups to classify them
according to their localization (cytosol, cytoskeleton,
Golgi complex, mitochondria, cell membrane, and
other). The cytosol group of proteins is prevailing
(42.5%). The percent representation of the other locali-
zation groups are: cytoskeleton (19%), cell membrane
(18%), other (8.5%), Golgi complex (6%) and mitochon-
dria (6%). This representation has to be understood sim-
ply as an approximate attribute.
The pI and molecular weight (kDa) of all identified
proteins were estimated, as mentioned above. The esti-
mated experimental values were comparatively analyzed
against the calculated value of pI and molecular weight
of the identified proteins. Both pI and molecular weight
correlation plots were created (Figure 5). As expected,
comparative analysis of molecular weights showed a
stronger correlation (correlation coefficient 0.698) than
pI correlation (correlation coefficient 0.488) - this phe-
nomenon is discussed below. More precisely, 71% of the
identified proteins showed a difference of not more than
0.5 pI (protein database-based pI values of all proteins
in a single spot compared to the spot estimated pI); and
78% of proteins showed a difference less than 15 kDa
(in fact, 71% of proteins have a difference less than 8
kDa). Regardless of a strong correlation of protein MW
values, large differences between database-based MW
and experimental values were found in a few of the
identified proteins (thrombospondin-1, talin, filamin-A,
multimerin-1, etc.).
Correlation analysis was completed by the Progenesis
SameSpots software; and the results were shown in a
dendrogram tree (See additional file 2: Figure s6). All
Figure 2 Positions of significantly differed spots on a 2D gel. Positions of all spots that were found to significantly differ in 2D gels of
resting and activated (by arachidonic acid, collagen, and thrombin) platelets when mutually compared. The 2D gel of resting platelets was used
as an illustrative gel to display spot positions.
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spots in the dendrogram were grouped by their spot
expression profiles using automatic correlation analysis
and hierarchical clustering software. We intentionally
chose the top ten spot expression profile groups (with
Distance parameter less than 0.5; Distance is equal to 1-
C, where C is correlation between spot clusters) with
almost identical expression profiles. Thus, each group
contains spots with similar expression profiles suggest-
ing that these spots may be co-regulated, co-localized,
or by another way co-affected. The list of the expression
profile groups; including spot number, experimental and
calculated pI and Mw values, the protein identification,
and its accession number, is presented in Table 2 (See
additional file 1: Table s2). An example of the expres-
sion profile group from Table 2 (See additional file 1:
Table s2) is presented in Figure 7 (See additional file 3:
Figure s7). Spot expression profile group 2 is red colour
highlighted in the dendrogram and its expression profile
with observed overexpression in AA activated platelets
is presented.
All of the identified proteins except the five men-
tioned below were confirmed to be platelet proteins
using the UniProt, PlateletWeb (a database covering the
platelet proteome, transcriptome, and interactome, con-
taining information from published platelet proteome
and transcriptome studies) [18] and BRENDA databases
and literature. We found five proteins that have not
been identified in platelets before: protein CDV3 homo-
log ([Swiss-Prot:Q9UKY7]; spot 72); protein ETHE1,
mitochondrial ([Swiss-Prot:O95571]; spot 139); protein
LZIC ([Swiss-Prot:Q8WZA0]; spot 151); FGFR1 onco-
gene partner 2 ([Swiss-Prot:Q9NVK5]; spot 154); and
guanine nucleotide-binding protein subunit beta-5
([Swiss-Prot:O14775]; spot 184).
Discussion
The aim of this study was to use proteomic tools to
explore the human platelet proteome and to extend our
knowledge of proteome changes in activated platelets.
Isoelectric focusing, mini-gel format SDS-PAGE, and
Figure 3 2D SDS-PAGE of resting platelets. An illustrative 2D SDS-PAGE gel image of resting platelets without displayed positions of
significantly differed spots.
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colloidal Coomassie blue staining were used to resolve
and visualize proteins, together with nanoLC-MS/MS
for protein identification. We used statistical compara-
tive Progenesis SameSpots software to find proteome
differences and to perform spot (protein) expression
profile analysis. To obtain unique data not yet available
we decided to mutually compare resting platelets and
platelets activated by AA, collagen, and thrombin. In
this paper we present the list of spots with protein iden-
tifications that differ among these four mentioned
groups. All spots that significantly differed and fulfilled
the minimum criteria (p < 0.05, minimum fold change
1.2) were presented in the list of spots (See additional
file 1: Table s1). Chosen criteria allow us to compare
Figure 4 An example of six detected spots. Expression profiles with the logarithms of spot expression volumes and their standard deviations
for each group (resting platelets and by arachidonic acid, collagen, and thrombin activated platelets as indicated below the x-axis) are presented
for six spots. Gel areas containing the same spot from each group (one exemplary gel area from each group) are presented above the logarithm
values.
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other sets of results or simply reduce the list of spots by
changing the parameters. Cold acetone was used to pre-
cipitate both proteins contained in agregates and
released by activated platelets in the whole sample.
Released proteins thus remained in the sample and
therefore we could exclude the effect of the release reac-
tion on our results (e.g. on spot expression).
Despite the limits of the methods used, we have found
differences in 190 spots that correspond to 144 unique
open reading frames. Five of these proteins have not
been identified in platelets before.
Protein CDV3 homolog ([Swiss-Prot:Q9UKY7]; spot
72) is a cytoplasmatic protein of unknown function. It
probably plays a role in cell proliferation; and its expres-
sion is known to be changed in human breast cancer
cells [19]. It was found that this protein is phosphory-
lated [20,21] and acetylated [22,23]. We found a 2-fold
difference in spot normalized volumes when AA acti-
vated platelets (and slight difference in thrombin acti-
vated platelets) were compared with resting and
collagen activated platelets.
Protein ETHE1 ([Swiss-Prot:O95571], ethylmalonic
encephalopathy protein 1; spot 139) is probably involved
in mitochondria metabolic homeostasis; and it may act
as a nuclear-cytoplasmic shuttling protein [24]. ETHE1
overexpression has been observed in hepatoma. It is also
known that defects in ETHE1 are a cause of ethylmalo-
nic encephalopathy [25]. Although no enzymatic activity
of ETHE1 has yet been determined, sequence similarity
shows this protein belongs to the hydrolases. We
observed a change of spot normalized volume when AA
activated platelets were compared with other groups.
The spot 139 contains two proteins, ETHE1 together
with F-actin capping protein subunit beta ([Swiss-Prot:
Figure 5 pI and Mw correlation plots. A - Correlation between calculated (theoretical) and experimental pI values of all spots; B - Correlation
between calculated (theoretical) and experimental Mw values of all spots.
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P47756]) that is contained in another spots (78, 153,
154, 183). There is a similar spot expression profile
shared with spot 78. This indicates the possible postran-
slational modification of the F-actin capping protein
subunit beta, rather than a modification or concentra-
tion change of ETHE1.
Protein LZIC ([Swiss-Prot:Q8WZA0], leucine zipper
and ICAT homologous domain-containing protein; spot
151) is ubiquitously expressed (the highest level in the
kidney); and it seems to be up-regulated in gastric can-
cers [26]. The zebrafish homolog of human LZIC is
required for neuronal survival [27]. We found a differ-
ence in spot normalized volumes when AA activated
platelets were compared with other groups. A general
underexpression is observed in all activated groups
when compared to resting platelets.
FGFR1 oncogene partner 2 ([Swiss-Prot:Q9NVK5];
spot 154) is a cytoplasmic protein that may play a role
in the wound-healing pathway [28]. There is currently
no additional information on its function. This protein
is expressed in the bone marrow, spleen, and thymus.
Spot volume difference was observed comparing AA
and thrombin activated platelets to collagen activated
and resting platelets. The second protein identified in
the spot (154) is the F-actin capping protein subunit
beta ([Swiss-Prot:P47756]). The same spot expression
profile as in spot 154 can be observed in another spot
(153) containing the F-actin capping protein subunit
beta. A similar spot expression profile was found in the
spot (183) that contains the F-actin capping protein sub-
unit beta, together with another protein. This situation
is identical to that of spot 139 (protein ETHE1, dis-
cussed above); therefore, the data do not confirm the
modification or concentration change of FGFR1 onco-
gene partner 2.
Guanine nucleotide-binding protein subunit beta-5
([Swiss-Prot:O14775]; spot 184) belongs to the G-pro-
teins that are involved in various transmembrane signal-
ing systems [29]. Beta subunits are required for GTPase
activity and for G-protein-effector interaction. Similarly
to the previously mentioned proteins, we observed a dif-
ference in spot normalized volumes comparing AA and
thrombin activated platelets to collagen activated and
resting platelets. In this spot we have identified a second
protein: L-lactate dehydrogenase B chain ([Swiss-Prot:
P07195]), which was also found in other spots (82 and
149) that share the same spot expression profile. Assum-
ing this fact, we suppose that the spot volume difference
is related to the L-lactate dehydrogenase B chain.
As noted above, spot differences (139, 154, and 184)
can be apparently related to co-identified proteins.
There are only two proteins (CDV3 and LZIC) from the
five new proteins that were uniquely identified within
their spots. Both proteins’ changes were observed in AA
activated platelets. We do not assume that these changes
are caused by different protein concentrations, because
of platelets’ limited proteosynthesis capability [30] and
activation conditions (buffered washed isolated platelets
activated ex vivowithout the presence of either other
proteins or with traces of plasmatic proteins of the same
level in all four sample groups). Therefore, we assume
that these changes are caused by posttranslational modi-
fications of CDV3 and LZIC. This assumption is sup-
ported by the spot expression profiles of both proteins:
their spot normalized volumes are decreased when AA
activated platelets are compared to the resting platelet
group. The explanation of observing these changes in
AA activated platelets may be the involvement of both
CDV3 and LZIC proteins in the AA platelet activation
pathways via signal transduction or target affecting. A
general underexpression of LZIC protein is observed in
all activated groups (with strong underexpression in AA
activated platelets) when compared to resting platelets.
When searched LZIC protein sequence by blast protein
tool a putative conserved domain has been detected;
LZIC protein seems to belong to beta-catenin-interact-
ing protein superfamily. Beta-catenin is a multifunc-
tional protein involved in cell adhesion, cytoskeleton
organization (anchors actin cytoskeleton), signal trans-
duction, protein interactions etc. LZIC protein (zebrafish
and mouse) seems to interact with beta-catenin through
another protein (or proteins) instead of direct beta-cate-
nin and LZIC interaction [27]. Because platelet activa-
tion is accompanied by vast protein and generally
cytoskeleton reorganization (including actin cytoskele-
ton), and LZIC protein regulation (putative underex-
pression) was observed in all platelet activation groups
compared to resting platelet group, we suggest the pos-
sible LZIC protein involving in platelet cytoskeleton
reorganization during platelet activation process. The
mechanism of LZIC protein function in platelet activa-
tion may be closely related to AA activation pathways
because of stronger underexpression in AA activated
platelets and known relation of AA activation pathways
to other agonists’ pathways. Additional data knowledge
(characterization of eventual LZIC protein modification,
etc.) should support this assumption.
One of the most important protein posttranslational
modifications involved in platelet activation is phosphor-
ylation/dephosphorylation [31,32]. Phosphorylated/
dephosphorylated protein spots show a specific pI shift
or number of shifts when the protein is multiply-phos-
phorylated/dephosphorylated (also called spot trains).
Spot trains may be caused by modifications other than
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(de)phosphorylation; and they differ in the pI shift. We
did not observe any spot trains of the CDV3 and LZIC
spots (72 and 151), so the modification(s) seemed to
change substantially and rapidly pIs (not observed in
used 4-7 pI range) or molecular weights. This may be
caused, among other modifications, by glycosylation.
CDV3 and partially LZIC spot normalized volume
changes that were observed in AA activated platelets
could be caused by other nonspecific protein modifica-
tions. Platelet activation by AA (and platelet AA meta-
bolism) is known to generate large amounts of reactive
oxygen and nitrogen species (RONS) [33-35]. There are
another agonists (thrombin [36], collagen [34,37])
known to produce RONS during platelet activation, but
the generation of reactive species is concomitant with
AA metabolism [36]. RONS can be generated by NAD
(P)H oxidases (NOX), cyclooxygenase 1 (COX-1) and
other sources [35]. From the 2D PAGE view, RONS
activity can cause not only protein pI shifts, but also can
rapidly change protein molecular weights by the cross-
linking of proteins. This increase in protein molecular
weights can be so large that crosslinked proteins are not
able to be detected in the 2D gel (using a gradient gel
range of 5-15%). We found several carbonylated and tyr-
osyl nitrated platelet proteins in our preliminary study
when platelets were activated by AA, collagen, and
thrombin. Using western blotting we identified in this
way posttranslationally modified proteins - for example
fibrinogen beta and gamma chains, PDZ and LIM
domain protein 1, vinculin, gelsolin, talin-1, moesin and
other proteins [38].
Using spot (protein) expression profile analysis, we
chose deliberately the top ten discrete spot expression
profile groups (SEPG) (See additional file 1: Table s2).
This statistical tool contained in Progenesis SameSpots
software can be successfully used to extrapolate more
information from the measured data and to get a picture
of protein relations. It may help to find co-regulated, co-
localized, or proteins related by other means. Practically
three SEPG (groups 2-3 and 10) contain a simple pro-
tein in all their spots in each group (except spot 17 in
group 3 and other spot co-identified proteins). Group 2
comprises talin-1; and it seems to be strongly overex-
pressed in AA activated platelets. Group 3 contains
fibrinogen chains (beta and gamma); and it seems to be
strongly underexpressed in thrombin activated platelets.
This may be caused by an enzymatic activity of throm-
bin that splits fibrinopeptides A and B from released
fibrinogen and yields fibrin monomers polymerizing into
a fibrin net. Since platelets contain Factor XIII, catalyz-
ing the formation of covalent bonds between epsilon
aminogroups of lysine residues and gamma-carboxyl
groups of glutamic acid residues, the fibrin molecules
are covalently crosslinked. Fibrin crosslinking greatly
affected molecular weights, especially of gamma and
alpha fibrinogen chains (gamma-dimers, alpha poly-
mers); and consequently fibrinogen chains levels seem
to be underexpressed [39]. Group 10 contains almost
only thrombospondin-1 and seems to be strongly over-
expressed in thrombin activated platelets in accordance
with existing literature. Group 5 could be attached to
the previous three groups. More than half of the group
5 spots contain PDZ and LIM domain protein 1; and
two of the four remaining spots contain the same pair
of proteins (zyxin and serotransferrin). PDZ and LIM
domain protein 1 may act as an adapter that brings
other proteins to the cytoskeleton. We observed throm-
bin induced underexpression of this protein in accor-
dance with observed downregulation in TRAP activated
platelets [40]. Zyxin is an adhesion plaque protein and a
regulator of actin filament assembly. It has been
observed that zyxin changes its location (translocation
to the platelet surface) in thrombin activated platelets
[41] and the protein was found at the peripheral mem-
brane in a differential study of GPVI activated platelets
[42]. It has been further shown that zyxin is released
from platelets activated by thrombin [43].
There is a category of several SEPG, consisting espe-
cially of cytoskeletal proteins (groups 1-2, 8-9). Protein
spots of these groups seem to be strongly overexpressed
in AA activated platelets (groups 1-2); or they embody a
similar spot expression profile (groups 8-9), with puta-
tive overexpression in AA and in thrombin activated
platelets. The platelet cytoskeleton is rapidly rearranged
during platelet activation; and thus cytoskeletal proteins
are generally modified to carry out their function. Other
factors that can play an important role in protein
expression changes are the reactive oxygen and nitrogen
species generated during the process of platelet activa-
tion, especially in AA activated platelets. The effects of
RONS on the modification of proteins were discussed
above.
In the three remaining SEPG (4, 6, and 7), group 4
seems to be slightly underexpressed in thrombin acti-
vated platelets. This group contains primarily two pro-
teins (pseudo-underexpression of fibrinogen chains was
discussed in group 3): WD repeat-containing protein 1
and mitochondrial glycerol-3-phosphate dehydrogenase.
WD repeat-containing protein 1 is a cytosolic protein
involved in the disassembly of actin filaments. The protein
is released by platelets during platelet activation by throm-
bin [43]. It has been observed that it is translocated to the
platelet surface by stimulation with thrombin [41]. More-
over, it has been shown that WD repeat-containing
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protein 1 interacts with the platelet integrin aIIb regula-
tory motif [44]. Its possible phosphorylation in thrombin
activated platelets has been noted [45]. Mitochondrial gly-
cerol-3-phosphate dehydrogenase (a component of the
glycerol phosphate shuttle) is located on the outer surface
of the inner mitochondrial membrane. Because of the dif-
ferent localization of both proteins, we can exclude protein
modification due to co-localization; and these proteins
may be part of the thrombin specific activation or signal
transduction pathway(s). Glycerol-3-phosphate dehydro-
genase is involved in mitochondria energy production and
thus either changes of its presence or its PTM might be
expected in all platelet preparations activated indepen-
dently with the three mentioned agonists. Surprisingly,
only in thrombin activated platelets both the spots 26 and
71, containing glycerol-3-phosphate dehydrogenase, show
strong underexpression (2.8 and 2.0 fold change) and no
change in their expression was observed in AA or collagen
activated platelets and in resting platelets. We have not yet
obtained any information about possible PTMs of these
proteins that could induce underexpression. Nevertheless,
the phosphorylation of WD repeat-containing protein 1
and oxidative modifications of both proteins might be
probably present. Due to different localizations of both
proteins in platelets we speculate that these SEPG 4 pro-
teins can mutually interact via another protein or proteins.
The absence of such interaction-mediator(s) in SEPG 4
can be explained by the limits of 2D electrophoresis
(detection and pI range limits etc.).
Group 6 contains several cytoplasmatic and cytoskele-
tal proteins. The majority of them are components of
the cytoskeleton or are involved in cytoskeleton reorga-
nization and interaction. This group of spots differs
slightly in AA activated platelets and could be classified
with the other spot groups containing cytoplasmatic
proteins changed in AA activated platelets (groups 1-2,
8-9). Group 7 contains proteins that were changed in
activated platelets, no matter which agonist was used for
activation. This probably indicates that all of these pro-
teins may be involved in platelet activation pathways or
other differing functions that generally take place in
activated platelets. For example, mitochondrial thiore-
doxin-dependent peroxide reductase is an enzyme that
is involved in the redox regulation of the cell and pro-
tects other enzymes from oxidative damage (which is
increased during platelet activation) [46].
Many of proteins identified in this study have been
found to change their expression agonist-dependently.
As an example, thrombospondin-1 which is changed in
thrombin activated platelets (spots 1, 9, 79 etc.) is an
adhesive glycoprotein and is involved in platelet aggre-
gation. Glutathione peroxidase 1 changed in collagen
activated platelets (spots 3, 23, 25 and 42) protects from
oxidative stress. Filamin-A changed in AA activated pla-
telets (spots 7, 20, 22 and 98) is involved in actin cytos-
keleton reorganization. Talin-1 changed in AA activated
platelets (spots 10, 24, 58 etc.) is involved in cytoskele-
ton reorganization.
In spite of repeated MS/MS analysis, ten spots of
detected 190 spots, that significantly differed in the nor-
malized volumes, did not yield any valid spectra. There-
fore, the proteins present in these spots remained
unidentified. All of these spots had relatively low mole-
cular weight (the most of them with MW lower than 13
kDa), thus the amount of tryptic peptides might not be
sufficient for the identification. These peptides could
also be lost in the pre-concentration step during
nanoLC-MS/MS analysis, due to their low affinity with
the C18 TRAP column. Moreover, these proteins can be
proteoglycans yielding fewer tryptic peptides. The profile
analysis of these spots expression (data not shown) indi-
cates a group of five spots that could contain the same
protein or a group of the same proteins. These spots
(19, 39, 45, 46, and 51) represent the same expression
profile; and their molecular weights are similar.
The comparative analysis of protein molecular weights
showed a stronger correlation than the pI analysis. This
indicates that most protein changes can be assigned to
posttranslational modifications (phosphorylation, oxida-
tion, etc.). These modifications only slightly change pro-
tein molecular weights in 2D PAGE maps, but can
notably affect the pI of proteins. By contrast, we observed
several proteins showing a significant difference in esti-
mated and calculated molecular weights (thrombospon-
din-1, talin, filamin-A, etc.). However, no identification of
intact proteins (of the calculated molecular weight) cor-
responding to those fragments was observed. Similar
results have been already reported by other authors [47].
Conclusions
In conclusion, the reported data show substantial
changes in proteomes of platelets activated by various
agonists. We found five proteins that have not been
identified in platelets before. Several proteins have
been found to change agonist dependently. Two candi-
date thrombin pathway specific proteins have been
identified: WD repeat-containing protein 1 and mito-
chondrial glycerol-3-phosphate dehydrogenase. Never-
theless, further investigation has to be done to clarify
their meaning in the thrombin activation pathway. Our
results, characterizing the differences in proteins in
activated and resting platelets, contribute to the basic
knowledge of platelets and to development of new
antiplatelet drugs.
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Additional material
Additional file 1: Additional Tables 1 and 2. Table 1 - List of spots
that significantly differ in activated platelets. Table 2 - Top ten spot
expression profile groups.
Additional file 2: Figure 6 - The dendrogram tree. The dendrogram
tree - a visual representation of the spot correlation data of all spots that
were found to be significantly different among all four platelet groups
(resting and activated platelets) when mutually compared.
Additional file 3: Figure 7 - An example of the expression profile
group (group 2). A - The dendrogram tree with highlighted (in red
colour) spots of spot expression profile group 2. The x-axis is composed
of all 190 spots that significantly differed when resting and by different
agonist activated platelet proteomes were mutually compared. Spots are
grouped by their expression patterns using correlation analysis and
hierarchical clustering.; B - The expression profile of spot expression
profile group 2 spots. All spots for each activation group (resting
platelets and by arachidonic acid, collagen, and thrombin activated
platelets as indicated below the x-axis) are displayed.
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